MX2022014637A - Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta. - Google Patents
Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.Info
- Publication number
- MX2022014637A MX2022014637A MX2022014637A MX2022014637A MX2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A MX 2022014637 A MX2022014637 A MX 2022014637A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- dehydrogenase activity
- chain dehydrogenase
- modulating
- Prior art date
Links
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 title 1
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 abstract 3
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos y métodos para modular la actividad de 15-PGDH, modular los niveles de prostaglandina tisular, tratar enfermedades, trastornos de enfermedades o estados donde se desea modular la actividad de 15-PGDH y/o los niveles de prostaglandinas incluyen inhibidores de 15-PGDH descritos en el presente documento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063027557P | 2020-05-20 | 2020-05-20 | |
PCT/US2021/033170 WO2021236779A1 (en) | 2020-05-20 | 2021-05-19 | Compositions and methods of modulating short-chain dehydrogenase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014637A true MX2022014637A (es) | 2023-03-03 |
Family
ID=76444602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014637A MX2022014637A (es) | 2020-05-20 | 2021-05-19 | Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230192717A1 (es) |
EP (1) | EP4153299A1 (es) |
JP (1) | JP2023527279A (es) |
KR (1) | KR20230053551A (es) |
CN (1) | CN116507626A (es) |
AR (1) | AR122137A1 (es) |
AU (1) | AU2021275122A1 (es) |
BR (1) | BR112022023576A2 (es) |
CA (1) | CA3183262A1 (es) |
CL (1) | CL2022003255A1 (es) |
CO (1) | CO2022018365A2 (es) |
CR (1) | CR20220654A (es) |
IL (1) | IL298043A (es) |
MX (1) | MX2022014637A (es) |
PE (1) | PE20230777A1 (es) |
TW (1) | TW202208376A (es) |
UY (1) | UY39225A (es) |
WO (1) | WO2021236779A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
CN114861214B (zh) * | 2022-07-08 | 2022-10-14 | 智控天下(北京)商业管理有限公司 | 业务数据监控方法、设备、存储介质及装置 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US568159A (en) | 1896-06-26 | 1896-09-22 | Veneering-machine | |
US3382248A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines |
US4910226A (en) | 1987-04-29 | 1990-03-20 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
LU87308A1 (fr) | 1988-08-01 | 1990-03-13 | Oreal | Nouveaux derives de diamino-2,4 pyrimidine oxyde-3 et leur utilisation pour le traitement et la prevention de la chute des cheveux |
US5015629A (en) | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
FR2651122B1 (fr) | 1989-08-29 | 1994-10-28 | Oreal | Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3. |
US5480913A (en) | 1989-09-27 | 1996-01-02 | Arch Development Corporation | Anti-androgen compounds |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
FR2662607B1 (fr) | 1990-05-30 | 1992-08-28 | Oreal | Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 . |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
FR2677884B1 (fr) | 1991-06-20 | 1993-07-09 | Oreal | Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues. |
FR2678929A1 (fr) | 1991-07-11 | 1993-01-15 | Oreal | Compositions pour freiner la chute des cheveux et pour induire et stimuler leur croissance a base de derives de 2,4-diamino pyrimidine 3-oxyde, nouveaux derives 2,4-diamino pyrimidine 3-oxyde. |
FR2683531B1 (fr) | 1991-11-13 | 1993-12-31 | Rhone Poulenc Rorer Sa | Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent. |
US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
TW369521B (en) | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
FR2711060B1 (fr) | 1993-10-13 | 1995-11-17 | Oreal | Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet. |
SE9303444D0 (sv) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
FR2719481B1 (fr) | 1994-05-05 | 1996-05-31 | Oreal | Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux. |
US5516779A (en) | 1994-06-08 | 1996-05-14 | Merck & Co., Inc. | 17β-substituted-6-azasteroid derivatives useful as 5α-reductase inhibitors |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5807895A (en) | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
US5529769A (en) | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
FR2732597B1 (fr) | 1995-04-05 | 1997-05-16 | Oreal | Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6 |
US5631282A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | Triterpenes |
JPH10215356A (ja) | 1996-11-27 | 1998-08-11 | Fuji Photo Film Co Ltd | 再プリント用写真画像データの保管方法およびシステム |
CA2279967C (en) | 1997-02-04 | 2006-08-22 | Murray A. Johnstone | Method of enhancing hair growth |
CA2315266C (en) | 1997-12-12 | 2004-08-10 | University Of Southern California | Wound healing compositions |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
AU4466901A (en) | 2000-03-31 | 2001-10-08 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020146439A1 (en) | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
FR2812190B1 (fr) | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
FR2812191B1 (fr) | 2000-07-28 | 2003-10-17 | Oreal | Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques |
FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
WO2013158649A1 (en) | 2012-04-16 | 2013-10-24 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
EP2922543B1 (en) | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
CA2927730A1 (en) | 2013-10-15 | 2015-05-07 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
AU2016229918B2 (en) | 2015-03-08 | 2020-10-29 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating fibrosis |
CA2982784A1 (en) | 2015-04-14 | 2016-10-20 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
EP3484473A4 (en) | 2016-07-18 | 2020-03-18 | Case Western Reserve University | INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY TO PROMOTE NEUROGENESIS AND INHIBIT NERVOUS CELL DEATH |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
EP3606520A4 (en) | 2017-04-07 | 2021-01-06 | Case Western Reserve University | SHORT CHAIN DEHYDROGENASE ACTIVITY INHIBITORS FOR THE TREATMENT OF CORONARY DISORDERS |
WO2018218251A1 (en) | 2017-05-26 | 2018-11-29 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
JP2022507888A (ja) * | 2018-11-21 | 2022-01-18 | ケース ウェスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法 |
JP7027301B2 (ja) | 2018-12-25 | 2022-03-01 | アルタカ株式会社 | スクリーン印刷用版枠 |
JP2020134242A (ja) | 2019-02-15 | 2020-08-31 | オリンパス株式会社 | 計測方法、計測装置、およびプログラム |
-
2021
- 2021-05-19 JP JP2022570143A patent/JP2023527279A/ja active Pending
- 2021-05-19 EP EP21732686.7A patent/EP4153299A1/en active Pending
- 2021-05-19 CA CA3183262A patent/CA3183262A1/en active Pending
- 2021-05-19 TW TW110118083A patent/TW202208376A/zh unknown
- 2021-05-19 AU AU2021275122A patent/AU2021275122A1/en active Pending
- 2021-05-19 MX MX2022014637A patent/MX2022014637A/es unknown
- 2021-05-19 BR BR112022023576A patent/BR112022023576A2/pt unknown
- 2021-05-19 PE PE2022002693A patent/PE20230777A1/es unknown
- 2021-05-19 KR KR1020227044581A patent/KR20230053551A/ko active Search and Examination
- 2021-05-19 CR CR20220654A patent/CR20220654A/es unknown
- 2021-05-19 WO PCT/US2021/033170 patent/WO2021236779A1/en active Application Filing
- 2021-05-19 CN CN202180036167.1A patent/CN116507626A/zh active Pending
- 2021-05-19 IL IL298043A patent/IL298043A/en unknown
- 2021-05-19 US US17/926,214 patent/US20230192717A1/en active Pending
- 2021-05-20 AR ARP210101381A patent/AR122137A1/es unknown
- 2021-05-20 UY UY0001039225A patent/UY39225A/es unknown
-
2022
- 2022-11-18 CL CL2022003255A patent/CL2022003255A1/es unknown
- 2022-12-17 CO CONC2022/0018365A patent/CO2022018365A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023527279A (ja) | 2023-06-28 |
EP4153299A1 (en) | 2023-03-29 |
CL2022003255A1 (es) | 2023-07-14 |
BR112022023576A2 (pt) | 2023-02-07 |
WO2021236779A9 (en) | 2022-01-13 |
AU2021275122A1 (en) | 2022-12-15 |
AR122137A1 (es) | 2022-08-17 |
CN116507626A (zh) | 2023-07-28 |
WO2021236779A1 (en) | 2021-11-25 |
CR20220654A (es) | 2023-08-24 |
KR20230053551A (ko) | 2023-04-21 |
UY39225A (es) | 2021-11-30 |
CO2022018365A2 (es) | 2023-03-07 |
CA3183262A1 (en) | 2021-11-25 |
TW202208376A (zh) | 2022-03-01 |
PE20230777A1 (es) | 2023-05-09 |
IL298043A (en) | 2023-01-01 |
US20230192717A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021551169A1 (en) | Compositions and methods of modulating short-chain dehydrogenase activity | |
CR20220654A (es) | Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta | |
CR20210516A (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
PH12020551208A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
CL2021002681A1 (es) | Inhibidores de la dihidroorotato deshidrogenasa. | |
MX2021008400A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
MX2022009116A (es) | Inhibidores de pgdh y metodos de fabricacion y uso. | |
CR20220325A (es) | Fluoroalquil-oxadiazoles y sus usos | |
BR112015022575A2 (pt) | composto de fórmula, pró-droga de um composto, kit, métodos para regular uma trajetória, para regular qualquer uma ou mais dentre enzimas, para reduzir metabólitos, para alterar níveis de triptofano, para tratar supressão imunológica, para reduzir ou eliminar um distúrbio imunomediado, para inibir a ativação de enzimas, para tratar uma doença, para inibir uma produção de anticorpo autoimune, para preparar um composto e para diagnosticar e tratar uma doença e composto obtenível por um método | |
MX2022014351A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
MX2021012391A (es) | Composiciones y metodos para mejorar la salud de la piel y para el tratamiento y la prevencion de enfermedades, trastornos y afecciones asociados con microbios patogenos. | |
CR20230517A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
EP3989992A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR USE OF SEROTONIN MODULATION MICROBIOMIC-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | |
MX2023002953A (es) | Inhibidores de proteína tirosina fosfatasa y métodos para su uso. | |
MX2022007441A (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. | |
BR112018014920A2 (pt) | métodos de autofagia por modulação, de tratamento ou redução da probabilidade do início de uma condição mediada por autofagia, de tratamento, inibição, redução, diminuição, ou prevenção de um distúrbio relacionado à idade, de modulação da expressão ou atividade de pelo menos um fator de transcrição, de tratamento, prevenção, diminuição, inibição ou redução de uma condição patológica atribuível a um estado de excesso de nutriente, de promoção de longevidade por autofagia por modulação, de aumento da duração de tempo que um mamífero pode levar um estilo de vida ativo sem sofrer de condições associadas com envelhecimento e de prolongamento do período de saúde de um mamífero. | |
CA3139156A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
MX2022002245A (es) | Compuesto y metodos para tratar enfermedades relacionadas con oxalato. | |
MX2022004335A (es) | Biarilos como inhibidores de la dihidroorotato deshidrogenasa. | |
MX2022002443A (es) | Compuestos inhibidores de perk. | |
EP4257128A3 (en) | Methods and compounds for the treatment of genetic disease | |
MX2023003731A (es) | Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos. | |
WO2023147513A3 (en) | Compositions of autophagy modulating agents and uses thereof | |
MX2023001950A (es) | Compuestos y formulaciones para el tratamiento de enfermedades oftalmicas. | |
WO2024026483A3 (en) | Cdk2 inhibitors and methods of using the same |